Children’s Hospital of Philadelphia to study medical marijuana and autism

“This is truly an observational study,” Zuppa said. “We’re not giving them anything. We’re just gathering data to educate ourselves.” Children’s Hospital of Philadelphia is pairing with an Australian biopharmaceutical company in what some advocates say could be the first major effort in the United States to study the effects of medical marijuana on children with…

Medical marijuana for children with cancer? What providers think

A study published in Pediatrics examined interdisciplinary provider perspectives on legal medical marijuana use in children with cancer. It found that 92 percent of providers were willing to help children with cancer access medical marijuana. However, providers who are legally eligible to certify for medical marijuana were less open to endorsing its use. While nearly…

Queensland Bauxite to Test World First Cannabis Pain Relief Pill

Queensland Bauxite plans to test a “world first” cannabis pain relief pill in Australia under an agreement with a group of US chemists. Vitacann, owned by Queensland Bauxite’s Medical Cannabis subsidiary, signed a “letter of intent” to join forces with the unnamed group of chemists to manufacture pills for short and extended pain relief. Queensland…

Therapeutic Value of Medical Marijuana in New Jersey Patients: A Community Partnership Research Endeavour

The Public Health Program at Stockton University partnered with the Compassionate Care Foundation to ascertain the impact of medical marijuana on patients in New Jersey. Patients volunteered to complete a survey once a month for 8 months. The survey explored their use, form, and strain of medical marijuana and its influence on pain and 12 other physical and mental health variables. Also, an increase or decrease in other medication taken and any unexpected outcomes were recorded. Results support positive therapeutic benefits of medical marijuana, and despite methodological limitations, our study contributes to the growing body of literature.

Implications of prescription drug monitoring and medical cannabis legislation on opioid overdose mortality

Ecological study estimating opioid-related mortality in states with and without a prescription drug monitoring program (PDMP) and/or medical cannabis legislation. The relationship between PDMPs with mandatory access provisions, medical cannabis legislation, and opioid-related mortality rates. When combined with the availability of medical cannabis as an alternative analgesic therapy, PDMPs may be more effective at decreasing opioid-related mortality.